4//SEC Filing
Gibson Christopher 4
Accession 0001856369-25-000014
CIK 0001601830other
Filed
Nov 18, 7:00 PM ET
Accepted
Nov 19, 7:37 PM ET
Size
23.4 KB
Accession
0001856369-25-000014
Insider Transaction Report
Form 4
Gibson Christopher
Director
Transactions
- Conversion
Class A Common Stock
2025-11-19+40,000→ 953,839 total - Conversion
Class B Common Stock
2025-11-19−40,000→ 4,823,334 totalExercise: $0.00→ Class A Common Stock (40,000 underlying) - Sale
Class A Common Stock
2025-11-19$4.16/sh−40,000$166,400→ 913,839 total - Tax Payment
Class A Common Stock
2025-11-17$4.14/sh−40,390$167,215→ 913,839 total
Holdings
- 1,050,567
Stock Option (Right to Buy)
Exercise: $7.25Exp: 2035-02-03→ Class A Common Stock (0 underlying) - 399,002
Stock Option (Right to Buy)
Exercise: $11.40Exp: 2032-02-04→ Class A Common Stock (0 underlying) - 5,436
Stock Option (Right to Buy)
Exercise: $11.40From: 2022-02-04Exp: 2032-02-04→ Class A Common Stock (0 underlying) - 386,000(indirect: By LLC)
Class B Common Stock
Exercise: $0.00→ Class A Common Stock (0 underlying) - 282,500
Stock Option (Right to Buy)
Exercise: $2.48Exp: 2030-12-30→ Class A Common Stock (0 underlying) - 388,000(indirect: By LLC)
Class B Common Stock
Exercise: $0.00→ Class A Common Stock (0 underlying) - 50,000(indirect: By Trust)
Class B Common Stock
Exercise: $0.00→ Class A Common Stock (0 underlying) - 666,898
Stock Option (Right to Buy)
Exercise: $10.09Exp: 2034-02-09→ Class A Common Stock (0 underlying) - 813,600
Stock Option (Right to Buy)
Exercise: $8.55Exp: 2033-02-01→ Class A Common Stock (0 underlying)
Footnotes (11)
- [F1]Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units.
- [F10]The option, originally for 416,350 shares, vested as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2022, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter.
- [F11]The option, originally for 1,500,000 shares, vested as to one forty-eighth (1/48th) of the shares subject to the option on January 31, 2021, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.
- [F2]This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 12, 2025.
- [F3]Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date.
- [F4]The shares are held by LAHWRAN-3 LLC, of which the Reporting Person is a member and a manager.
- [F5]The shares are held by LAHWRAN-4 LLC, of which the Reporting Person is a member and a manager.
- [F6]The shares are held by the Gibson Family Trust, of which the Reporting Person serves as Trustee.
- [F7]The option vests as to one forty-eighth (1/48th) of the original 666,898 shares subject to the option on March 1, 2024, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter.
- [F8]The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2025, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter.
- [F9]The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2023, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter.
Documents
Issuer
RECURSION PHARMACEUTICALS, INC.
CIK 0001601830
Entity typeother
Related Parties
1- filerCIK 0001856369
Filing Metadata
- Form type
- 4
- Filed
- Nov 18, 7:00 PM ET
- Accepted
- Nov 19, 7:37 PM ET
- Size
- 23.4 KB